Showcase

公司名稱 Company Name

華輝安健(香港)有限公司
Huahui Health (Hong Kong) Co., Limited

公司網站 Company Website 

公司簡介 Company Background
華輝集團在HSITP合作將圍繞“產、學、研、商”四方面開展。將努力爭取達成以下目標:在肝病創新藥或檢測試劑盒領域形成合作項目意向;形成在港新建研發實驗室的可行方案;力爭促成IP海外BD交易;初步搭建公司首款創新藥立貝韋塔面向全球的藥品出口、中轉平臺。
Founded in Beijing in 2015, Huahui Health is a biopharmaceutical company dedicated to developing first-in-class and best-in-class therapies, with a strategic focus on viral hepatitis, liver diseases, and oncology. Driven by a patient-centric philosophy and profound scientific expertise, Huahui Health operates under the core principles of Innovation, Integrity, Collaboration, and Mutual Benefit. Huahui Health has built integrated, world-class proprietary platforms that cover the entire new drug development process, ensuring sustained delivery of breakthrough therapies for patients worldwide.
陳列產品之簡介 Description of displayed product
立貝韋塔單抗注射液於2026年1月23日獲得國家藥品監督管理局(NMPA)附條件批准,用於治療伴有或不伴有代償期肝硬化的慢性丁型肝炎病毒(HDV)感染成年患者。立貝韋塔單抗是病毒性肝炎治療領域的突破性成果,是該領域全球首個獲批的抗體類藥物,也是中國首個丁肝治療藥物,填補國內該領域治療空白。
Janaury 23,2026,China National Medical Products Administration (NMPA) has granted conditional approval to Libevitug injection for the treatment of chronic hepatitis D virus infection in adults with or without compensated cirrhosis. Libevitug is a human monoclonal antibody targeting the PreS1 domain of the large envelope protein of hepatitis B virus (HBV) and hepatitis D virus (HDV), thereby blocking viral entry into hepatocytes. As a groundbreaking achievement in viral hepatitis therapeutics, Libevitug is a first-in-class antibody therapeutic for viral hepatitis and the first approved treatment for HDV in China, addressing a major clinical gap in this field.
公司產品 Company products